Monday, May 6, 2013

BSE-associated Prion-Amyloid Cardiomyopathy in Primates

Volume 19, Number 6—June 2013


Dispatch



BSE-associated Prion-Amyloid Cardiomyopathy in Primates



Susanne Krasemann, Giulia Mearini, Elisabeth Krämer, Katja Wagenführ, Walter Schulz-Schaeffer, Melanie Neumann, Walter Bodemer, Franz-Josef Kaup, Michael Beekes, Lucie Carrier, Adriano Aguzzi1, and Markus Glatzel1Comments to Author
Author affiliations: University Medical Center Hamburg-Eppendorf, Hamburg, Germany (S. Krasemann, G. Mearini, E. Krämer, M. Neumann, L. Carrier, M. Glatzel); Robert Koch Institute, Berlin, Germany (K. Wagenführ, M. Beekes); University Hospital Göttingen, Göttingen, Germany (W. Schulz-Schaeffer); German Primate Center, Göttingen (W. Bodemer, F.-J. Kaup); University of Zurich, Zurich, Switzerland (A. Aguzzi)
 
 

Abstract





Prion amyloidosis occurred in the heart of 1 of 3 macaques intraperitoneally inoculated with bovine spongiform encephalopathy prions. This macaque had a remarkably long duration of disease and signs of cardiac distress. Variant Creutzfeldt-Jakob disease, caused by transmission of bovine spongiform encephalopathy to humans, may manifest with cardiac symptoms from prion-amyloid cardiomyopathy.



 
Human prion diseases are progressive neurologic disorders that include sporadic, genetic, and acquired forms of Creutzfeldt-Jakob disease (CJD) (1). A key step in disease initiation is conversion of PrPC into PrPSc, which is partially resistant to proteolytic digestion and an essential part of prion infectivity. Transmission of bovine spongiform encephalopathy (BSE) to humans has led to a novel form of acquired CJD, termed variant CJD (vCJD) (2). The pathogenesis of vCJD differs substantially from sporadic CJD with remarkable colonization of non–central nervous system regions with infectious prions and PrPSc (3).
 
 
 
 
Although risk reduction measures have been introduced to limit transmission from BSE-diseased cattle to humans, vCJD has occurred in several hundred instances (www.eurocjd.ed.ac.uk). Most clinically affected vCJD patients are homozygous for methionine on polymorphic codon 129 on the gene coding PrP (PRNP), and the clinical presentation of vCJD in these patients is uniform (4). The occurrence of atypical clinical features in persons with vCJD that encodes methionine and valine on PRNP codon 129 and human-to-human transmission of vCJD through blood transfusion have raised concern about atypical clinical features and alternative distribution of PrPSc in vCJD (5). We report on the novel clinicopathologic characteristics of vCJD as prion-amyloid cardiomyopathy in 1 of 3 macaques inoculated with BSE.
 
 
 
 

The Study

Figure 1
Thumbnail of PrPSc distribution and content in brain of bovine spongiform encephalopathy (BSE)–infected rhesus macaques. A) Paraffin-embedded tissue blot of striatum and cerebellum show a typical BSE-like deposition pattern of PrPSc with no differences between individual BSE-diseased monkeys at 49, 59, and 61 months postinoculation (mpi). Scale bar = 1 mm. B) Western blot analysis for PrPSc in brain of BSE-infected monkeys with incubation times of 49, 59, and 61 mpi. PrPSc-type is as expected fo



Figure 1. . PrPSc distribution and content in brain of bovine spongiform encephalopathy (BSE)–infected rhesus macaques. A) Paraffin-embedded tissue blot of striatum and cerebellum show a typical BSE-like deposition pattern of PrPSc with...



 
In 2002, three rhesus macaques were inoculated with BSE intraperitoneally (10 mL of a 10% homogenate of brain from BSE-diseased cattle). As controls, 2 rhesus macaques received saline (10 mL) and 1 was untreated. All procedures involving rhesus macaques were performed at the Institute of Neuropathology, University Medical Center Hamburg-Eppendorf (Hamburg, Germany), in accordance with the German Animal Welfare Act and the Council Directive 86/609/EEC (Permit 33.42502/08–08.02 LAVES, Lower Saxony, Germany). Animals were observed for clinical signs of prion disease and, when signs of terminal prion disease became evident, were euthanized and underwent autopsy. In all 3 BSE-challenged macaques and none of the controls a progressive neurologic disease developed 49, 59, and 61 months postinoculation. Examination of brain by using hematoxylin and eosin staining showed typical neuropathologic features of vCJD (data not shown) and abundant deposits of PrPSc in the cortex, basal ganglia, and cerebellum in paraffin-embedded tissue blots performed as described by using 12F10 monclonal antiprion antibody (6) (Figure 1, panel A). The mobility of the unglycosylated PrPSc band and the glycoform ratio of proteinase K–digested PrPSc were similar to those in BSE when assessed by Western blot analysis by using monoclonal POM-1 antiprion antibody as described (7) (Figure 1, panel B).

 
 
 
 
Figure 2
 
 
Thumbnail of Abundant PrPSc in heart of 1 bovine spongiform encephalopathy (BSE)–infected rhesus macaque. A) In sodium phosphotungstic acid precipitation of PrPSc, followed by Western blotting, highly abundant PrPSc was demonstrated in the heart of 1 BSE-infected primate. In this monkey, only the heart contained PrPSc. Controls include cardiac muscle spiked with minimal amounts brain of a healthy (–) and prion-diseased (+) primate. All analyses were prepared from 50 mg of tissue except the heart



Figure 2. . Abundant PrPSc in heart of 1 bovine spongiform encephalopathy (BSE)–infected rhesus macaque. A) In sodium phosphotungstic acid precipitation of PrPSc, followed by Western blotting, highly abundant PrPSc was demonstrated in...



 
Besides lymphoreticular tissues, the muscular compartment is targeted by prions (7,8). Thus, we assessed presence of PrPSc in skeletal and heart muscle by Western blot analysis with sodium phosphotungstic acid precipitation for enrichment of PrPSc and protein misfolding cyclic amplification by using published protocols (3). We could not detect substantial amounts of PrPSc in skeletal muscle (Figure 2, panel A). One macaque showed abundant PrPSc (≈1/100 of PrPSc found in brain) in heart in Western blot and protein misfolding cyclic amplification (Figure 2, panels A, B). Paraffin-embedded tissue blot analysis of this heart showed PrPSc as amyloid, occupying considerable stretches of heart tissue, mainly in the septum (Figure 2, panel C), whereas no PrPSc could be seen in hearts of other macaques (data not shown). These findings were confirmed by strong Congo red–positive patch-like depositions in cardiomyocytes in the heart of this monkey (Figure 2, panel D). The primate with cardiac PrPSc showed the longest disease duration (4 months, compared with 4 weeks for other BSE-infected monkeys), signs of cardiac affection when assessed by relevant makers of cardiac hypertrophy and of cardiac distress–associated inflammation, and only this macaque showed clinical signs of fatigue and signs of cardiac distress (i.e., venous congestion) on autopsy (Technical Appendix Adobe PDF file [PDF - 132 KB - 2 pages], Table). Histologic examination of heart tissue with hematoxylin and eosin staining and immunohistochemical stainings against B and T cells (CD20 [not shown] and CD3) did not provide evidence for toxic cardiomyopathy (i.e., fibrosis or vacuolization), nor did we find signs of inflammatory reaction (Figure 2, panel D).

 

 

Conclusions




 
Although the vCJD epidemic is declining, considerable concern exists that clinical characterastics of vCJD will shift. The most important genetic risk factor for development of vCJD is homozygosity for methionine on PRNP codon 129, and all but 1 patient with clinical vCJD carry this polymorphism (5). Thus, future cases of vCJD with longer incubation times are likely to comprise more patients with alternative codon 129 polymorphisms than methionine homozygosity. Data from rodent experiments indicate that clinical features of vCJD may differ in these patients (9). Thus, the next decades may see a shift in vCJD phenotypes. Further uncertainty for atypical cases in humans results from the possibility of secondary transmission of vCJD through blood products from subclinical carriers, which may lead to development of nonclassical vCJD phenotypes (5).





We showed that BSE infection of primates may occur as prion-amyloid cardiomyopathy. Because prion-amyloid cardiomyopathy developed in only 1 of 3 macaques, host-encoded factors, such as genetic makeup, probably influence development of this cardiac phenotype. All macaques are homozygous for methionine on PRNP codon 129; thus, prion-amyloid cardiomyopathy cannot be related to polymorphic codon 129 in our study (10). Cardiac involvement has been observed in a patient with sporadic CJD and is prominent in prion-diseased mice expressing PrPC lacking its membrane anchor (11,12). We considered the possibility that preexisting pathology, such as spontaneous cardiomyopathy or inflammation of the heart, might have contributed to cardiac PrPSc, and the fact that we did not find any evidence for toxic cardiomyopathy or inflammation in the primate does not exclude this possibility. Because the macaque with abundant PrPSc deposition in heart had longer disease duration, it is also possible that longer disease duration, which favors centrifugal spread of prions to peripheral tissues, contributed to cardiac affection in this primate (7). Peripheral deposition of PrPSc in vCJD is well studied (3). We were surprised by the amount and deposition type of PrPSc in heart, reaching 1/100 of the amount seen in brain and deposited as amyloid across large stretches of heart tissue. Skeletal muscle of prion-diseased patients and nonhuman primates routinely harbor minimal amounts of PrPSc (<1 and="" brain="" found="" in="" prp="" sup="" that="">Sc
in muscle is virtually impossible to detect by in situ methods (6,8,13). To our knowledge, PrPSc has not been detected in heart of vCJD-diseased persons or in patients with systemic amyloidosis, although primates orally exposed to BSE show very low amounts of cardiac PrPSc (8,14,15). The lack of cardiac PrPSc in vCJD may result from small cohorts investigated. Because the spectrum of vCJD is likely to change, broad application of current clinical criteria for vCJD in clinical practice may lead to underreporting of vCJD, missing atypical cases of vCJD.




In conclusion, we showed that BSE-infection of primates may lead to prion-amyloid cardiomyopathy. These data should be considered when vCJD surveillance is conducted.





Dr Krasemann is a research scientist at the Institute of Neuropathology of the University of Hamburg working on prion spread. Her primary research interests are factors involved in spread and clearance of prions.




 

Acknowledgments

This work was financed by the European Union grant EU BMH4 CT 98 7026, DFG grants KA 864/2-1, GL 589/2-1, and the BMBF-DLR grant 01GZ0712 to S.K.
The overall study was conceived and designed by M.G., A.A., F.J.K., and S.K. Animal care, housing, and observation were conducted by F.J.K., W.B., and W.S.S. Experiments were performed by S.K., G.M., E.K., K.W., W.S.S., and M.N. Data were analyzed by S.K., G.M., M.B., A.A., and M.G. S.K. and M.G. wrote the paper with substantial contributions from G.M. and A.A.




 

References





  1. Geissen M, Krasemann S, Matschke J, Glatzel M. Understanding the natural variability of prion diseases. Vaccine. 2007;25:56316. DOIExternal Web Site IconPubMedExternal Web Site Icon
  2. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A, A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347:9215. DOIExternal Web Site IconPubMedExternal Web Site Icon
  3. Wadsworth JDF, Joiner S, Hill AF, Campbell TA, Desbruslais M, Luthert PJ, Tissue distribution of protease resistant prion protein in variant CJD using a highly sensitive immuno-blotting assay. Lancet. 2001;358:17180. DOIExternal Web Site IconPubMedExternal Web Site Icon
  4. Heath CA, Cooper SA, Murray K, Lowman A, Henry C, MacLeod MA, Validation of diagnostic criteria for variant Creutzfeldt-Jakob disease. Ann Neurol. 2010;67:76170 .PubMedExternal Web Site Icon
  5. Kaski D, Mead S, Hyare H, Cooper S, Jampana R, Overell J, Variant CJD in an individual heterozygous for PRNP codon 129. Lancet. 2009;374:2128. DOIExternal Web Site IconPubMedExternal Web Site Icon
  6. Krasemann S, Neumann M, Geissen M, Bodemer W, Kaup FJ, Schulz-Schaeffer W, Preclinical deposition of pathological prion protein in muscle of experimentally infected primates. PLoS ONE. 2010;5:e13906. DOIExternal Web Site IconPubMedExternal Web Site Icon
  7. Glatzel M, Abela E, Maissen M, Aguzzi A. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N Engl J Med. 2003;349:181220. DOIExternal Web Site IconPubMedExternal Web Site Icon
  8. Peden AH, Ritchie DL, Head MW, Ironside JW. Detection and localization of PrPSc in the skeletal muscle of patients with variant, iatrogenic, and sporadic forms of Creutzfeldt-Jakob disease. Am J Pathol. 2006;168:92735. DOIExternal Web Site IconPubMedExternal Web Site Icon
  9. Asante EA, Linehan JM, Gowland I, Joiner S, Fox K, Cooper S, Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice. Proc Natl Acad Sci U S A. 2006;103:1075964. DOIExternal Web Site IconPubMedExternal Web Site Icon
  10. Glatzel M, Pekarik V, Luhrs T, Dittami J, Aguzzi A. Analysis of the prion protein in primates reveals a new polymorphism in codon 226 (Y226F). Biol Chem. 2002;383:10215. DOIExternal Web Site IconPubMedExternal Web Site Icon
  11. Trifilo MJ, Yajima T, Gu Y, Dalton N, Peterson KL, Race RE, Prion-induced amyloid heart disease with high blood infectivity in transgenic mice. Science. 2006;313:947. DOIExternal Web Site IconPubMedExternal Web Site Icon
  12. Ashwath ML, Dearmond SJ, Culclasure T. Prion-associated dilated cardiomyopathy. Arch Intern Med. 2005;165:33840. DOIExternal Web Site IconPubMedExternal Web Site Icon
  13. Herzog C, Sales N, Etchegaray N, Charbonnier A, Freire S, Dormont D, Tissue distribution of bovine spongiform encephalopathy agent in primates after intravenous or oral infection. Lancet. 2004;363:4228. DOIExternal Web Site IconPubMedExternal Web Site Icon
  14. Tennent GA, Head MW, Bishop M, Hawkins PN, Will RG, Knight R, Disease-associated prion protein is not detectable in human systemic amyloid deposits. J Pathol. 2007;213:37683. DOIExternal Web Site IconPubMedExternal Web Site Icon
  15. Herzog C, Riviere J, Lescoutra-Etchegaray N, Charbonnier A, Leblanc V, Sales N, PrPTSE distribution in a primate model of variant, sporadic, and iatrogenic Creutzfeldt-Jakob disease. J Virol. 2005;79:1433945. DOIExternal Web Site IconPubMedExternal Web Site Icon

Figures

Table

Technical Appendix



 
 
 
Suggested citation for this article: Krasemann S, Mearini G, Krämer E, Wagenführ K, Schulz-Schaeffer W, Neumann M, et al. BSE-associated prion-amyloid cardiomyopathy in primates. Emerg Infect Dis [Internet]. 2013 Jun [date cited]. http://dx.doi.org/10.3201/eid1906.120906External Web Site Icon
DOI: 10.3201/eid1906.120906




1These authors contributed equally to this article.





http://wwwnc.cdc.gov/eid/article/19/6/12-0906_article.htm








Monday, May 6, 2013


Warning of mad cow disease threat to blood transfusions


 








Wednesday, April 24, 2013
 
Dissociation between Transmissible Spongiform Encephalopathy (TSE) Infectivity and Proteinase K-Resistant PrPSc Levels in Peripheral Tissue from a Murine Transgenic Model of TSE Disease
 
 
 


 
 
Saturday, December 15, 2012
 
Bovine spongiform encephalopathy: the effect of oral exposure dose on attack rate and incubation period in cattle -- an update 5 December 2012

 
 
 
 
 
 
Friday, April 19, 2013
 
FDA BSE TSE PRION NEWS FEED AND ANNUAL INSPECTION OF FEED MILLS REPORTS HAS CEASED TO EXIST

 
 
 
 
 
 
Monday, March 25, 2013
 
Minnesota Firm Recalls Bone-In Ribeye That May Contain Specified Risk Materials Recall Release CLASS II RECALL FSIS-RC-024-2013

 
 
 
 
 
 
Tuesday, March 5, 2013
 
Use of Materials Derived From Cattle in Human Food and Cosmetics; Reopening of the Comment Period FDA-2004-N-0188-0051 (TSS SUBMISSION)

 
FDA believes current regulation protects the public from BSE but reopens comment period due to new studies

 
 
 
 
 
 
Wednesday, March 20, 2013
 
GAO-13-244, Mar 18, 2013 Dietary Supplements FDA May Have Opportunities to Expand Its Use of Reported Health Problems to Oversee Product
 
 
 
From: Terry S. Singeltary Sr.

 
Sent: Tuesday, March 19, 2013 2:46 PM

 
Cc: siggerudk@gao.gov ; youngc1@gao.gov ; oighotline@gao.gov

 
 
 
 
 
 
Wednesday, February 20, 2013
 
World Organization for Animal Health Recommends United States' BSE Risk Status Be Upgraded
 
 
 
Statement from Agriculture Secretary Tom Vilsack:

 
 
 
 
 
 
Thursday, February 14, 2013
 
The Many Faces of Mad Cow Disease Bovine Spongiform Encephalopathy BSE and TSE prion disease

 
 
 
 
 
 
Friday, April 19, 2013
 
Bovine Spongiform Encephalopathy (BSE) Feed Safety Support Program Grants Fiscal Year 2011: October 1, 2010 - September 30, 2011 FDA

 
 
 
 
 
 
Friday, April 19, 2013
 
 
APHIS 2013 Stakeholder Meeting (March 2013) BSE TSE PRION
 
 
 
 
 
 
 
 
Tuesday, April 30, 2013
 
 
Mad cow infected blood 'to kill 1,000’
 
 
 
 
 
 
Wednesday, April 24, 2013
 
Chimpanzees Released After 30 Years Of Testing, Brace Yourself For Smiles

 
 
 
 
 
 
Tuesday, April 30, 2013
 
Foodborne Transmission of Bovine Spongiform Encephalopathy to Nonhuman Primates

 
 
 
 



TSS

No comments:

Post a Comment